多项血清肿瘤酶标志物联合检测对原发性肝癌诊断的价值

本文对59例原发性肝癌(HCC)和97例其他肝病及消化道肿瘤患者进行了血清肿瘤酶标志物的联合测定。结果显示HCC组的r-谷氨酰转肽酶同工酶、碱性磷酸酶同工酶、醛缩酶同工酶及血清α-L-岩藻糖苷酶的活力均较正常组显著增高(P<0.01),四种酶联合检测对AFP(一)HCC的诊断阳性率为80％,与AFP联合检测对HCC总的诊断检出率达95.7％

COMBINED ASSAY OF SERUM TUMOR ENZYME MARKERS IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA

In order to evaluate combined serum tumor enzyme determinations in the diagnosis of hepatocellular carcinoma (HCC), four tumor markers including gamma-glutamyl tran- speptidase isoenzyme (r-GT-II), alkaline phosphatese isoenzyme (ALP-I), the ratio of the two aldolase activities, fructose-1, 6-diphosphoaldolase and fructose-1-phosphoaldo-lase (FDP/FIP) and a-L-fucosidase (AFU) were concomitantly determined in 59 patients with HCC, 97 patients with various liver diseases and gastrointestinal tumors. The results revealed that: (l)r-GT-II, ALP-I, FDP/FIP and AFU level were increased significantly in HCC (P<0.01); (2) The diagnostic sensitivity and specificity of these markers in HCC were r-GT-II(79.7%)>AFU(78.8%)>FDP/FIP(61%)>ALP-I(16.95%) and ALP-I(100%) >r-GT-II(92.l%)>AFU(90.9%)>FDP/FIP (88.8%), respectively; (3) The diagnostic positivity of combination assay was 80.0% in low or negative AFP producing HCC, while 95.7% in those with elevated AFP. Our data suggested that the combination assay of serum tumor enzyme markers was valuable in the diagnosis of HCC, especially in low or negative AFP HCC patients